|
|
| Zeile 99: |
Zeile 99: |
| | | | |
| | *'''[[The morbid survivor]]''' | | *'''[[The morbid survivor]]''' |
| − | {{tp|p=32219356|t=ä. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32369030|t=2020. Considerations for Postacute Rehabilitation for Survivors of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32224310|t=ä. Clinical and virological data of the first cases of COVID-19 in Europe: a case series |pdf=|usr=}}
| |
| − | {{tp|p=32164830|t=2020. COVID-19 with spontaneous pneumomediastinum |pdf=|usr=}}
| |
| − | {{tp|p=32229159|t=ä. SARS-CoV-2 infection presenting with hematochezia |pdf=|usr=}}
| |
| − | {{tp|p=32004427|t=2020. First Case of 2019 Novel Coronavirus in the United States |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32220650|t=ä. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32087116|t=2020. Asymptomatic cases in a family cluster with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32105632|t=ä. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study |pdf=|usr=}}
| |
| − | {{tp|p=32379729|t=2020. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32214079|t=2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32290644|t=2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India |pdf=|usr=}}
| |
| − | {{tp|p=32227758|t=ä. Covid-19 in Critically Ill Patients in the Seattle Region ? Case Series |pdf=|usr=}}
| |
| − | {{tp|p=32302078|t=ä. Clinical Characteristics of Covid-19 in New York City |pdf=|usr=}}
| |
| − | {{tp|p=32332185|t=2020. Care for adult non-ICU Covid-19 patients: early experiences from a Belgian tertiary care centre |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32309814|t=ä. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − | {{tp|p=32242121|t=ä. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | ---- | | ---- |
| Zeile 133: |
Zeile 109: |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − | {{tp|p=32363333|t=ä. A real-time dashboard of clinical trials for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}}
| |
| − | {{tp|p=32217166|t=2020. Chloroquine and COVID-19, where do we stand?? |pdf=|usr=}}
| |
| − | {{tp|p=32240719|t=ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344177|t=2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect |pdf=|usr=}}
| |
| − | {{tp|p=32305500|t=ä. Chloroquine paradox may cause more damage than help fight COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32255312|t=2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
| |
| − | {{tp|p=32316270|t=2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help |pdf=|usr=}}
| |
| − | {{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}}
| |
| − | {{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}}
| |
| − | {{tp|p=32187464|t=ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}}
| |
| − | {{tp|p=32275812|t=ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}}
| |
| − | {{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32366817|t=2020. A human monoclonal antibody blocking SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}}
| |
| − | {{tp|p=32358579|t=ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?|pdf=|usr=}}
| |
| − | {{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}}
| |
| − | {{tp|p=32355330|t=ä. Inactivated vaccine for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32327719|t=ä. Complement as a target in COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32346092|t=ä. Cancer therapy tool informs COVID-19 vaccines |pdf=|usr=}}
| |
| − | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
| |
| − | {{tp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}}
| |
| − | *[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]
| |
| − | {{tp|p=32286538|t=ä. Human antibodies can neutralize SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}}
| |
| − | {{tp|p=32327746|t=ä. Translating IL-6 biology into effective treatments |pdf=|usr=}}
| |
| − | {{tp|p=32341531|t=ä. Could BCG be used to protect against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32291449|t=ä. ADAM17 inhibition may exert a protective effect on COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32350818|t=ä. Chloroquine-induced QTc prolongation in COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 179: |
Zeile 116: |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32303482|t=ä. Re-emergence of SARS-CoV2 in a discharged COVID-19 case |pdf=|usr=}}
| |
| − | {{tp|p=32299784|t=ä. How do we decide to de-isolate COVID-19 patients?|pdf=|usr=}}
| |
| − | {{tp|p=32105304|t=2020. Positive RT-PCR Test Results in Patients Recovered From COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32276848|t=ä. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32224116|t=ä. Do children need a longer time to shed SARS-CoV-2 in stool than adults?|pdf=|usr=}}
| |
| − | {{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}}
| |
| − | {{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}}
| |
| − | {{tp|p=32214231|t=ä. COVID-19: faecal?oral transmission?|pdf=|usr=}}
| |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| − | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32294374|t=ä. Droplets and Aerosols in the Transmission of SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32129805|t=2020. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient |pdf=|usr=}}
| |
| − | {{tp|p=32203710|t=2020. Rational use of face masks in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344688|t=2020. 3-D Printed Protective Equipment during COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32322988|t=ä. Umgang mit COVID-19 in der Notaufnahme: Erfahrungsbericht der interdisziplinären Notaufnahme des Universitätsklinikums Münster |pdf=|usr=}}
| |
| − | {{tp|p=32329322|t=2020. In considerations of robotic colorectal surgery within a COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32327626|t=2020. Management of inflammatory bowel disease during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32225135|t=2020. Pathways for urology patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32202401|t=2020. Urology practice during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32253371|t=2020. Impact of the COVID-19 pandemic on urology residency training in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32368875|t=2020. Guide for Nuclear Medicine Applications During the COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32210421|t=2020. COVID-19 in intensive care Some necessary steps for health care workers |pdf=|usr=}}
| |
| − | {{tp|p=32297490|t=2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?|pdf=|usr=}}
| |
| − | {{tp|p=32278860|t=2020. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge |pdf=|usr=}}
| |
| − | {{tp|p=32335508|t=2020. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients |pdf=|usr=}}
| |
| − | {{tp|p=32334820|t=2020. The COVID-19 pandemic and the use of MS disease-modifying therapies |pdf=|usr=}}
| |
| − | {{tp|p=31986242|t=2020. Medical Journals and the 2019-nCoV Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32329975|t=ä. Covid-19 and Kidney Transplantation |pdf=|usr=}}
| |
| − | {{tp|p=32242095|t=ä. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32341524|t=ä. Cancer and COVID-19 ? potentially deleterious effects of delaying radiotherapy |pdf=|usr=}}
| |
| − | {{tp|p=32296166|t=ä. Provision of cancer care during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32214232|t=ä. Management of IBD during the COVID-19 outbreak: resetting clinical priorities |pdf=|usr=}}
| |
| − | {{tp|p=32249840|t=ä. Minimizing the risk of COVID-19 among patients on dialysis |pdf=|usr=}}
| |
| − | {{tp|p=32355296|t=ä. Combating physical inactivity during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32340751|t=ä. Manejo de la epidemia por coronavirus SARS-CoV-2 (Covid 19) en unidades de hemodialisis |pdf=|usr=}}
| |
| − | {{tp|p=32278616|t=ä. Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal |pdf=|usr=}}
| |
| − | {{tp|p=32348989|t=2020. Infection Control Measures for COVID-19 in the Labour Suite and Neonatal Unit |pdf=|usr=}}
| |
| − | {{tp|p=32335559|t=2020. Neonatal Resuscitation Where the Mother Has a Suspected or Confirmed Novel Coronavirus (SARS-CoV-2) Infection: Suggestion for a Pragmatic Action Plan |pdf=|usr=}}
| |
| − | {{tp|p=32325458|t=2020. COVID-19 and Neonatal Resuscitation |pdf=|usr=}}
| |
| − | {{tp|p=32196116|t=ä. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres |pdf=|usr=}}
| |
| − | {{tp|p=32339235|t=ä. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly |pdf=|usr=}}
| |
| − | {{tp|p=32289798|t=ä. Clinical Trials during the SARS-CoV-2 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32277236|t=ä. Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32319670|t=2020. Telemedicine in neurosurgery during the novel coronavirus (COVID-19) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32363507|t=ä. Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP) |pdf=|usr=}}
| |
| − | {{tp|p=32096116|t=2020. The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in Psychiatric Hospitals |pdf=|usr=}}
| |
| − | {{tp|p=32361728|t=ä. Letter: The Resiliency of the Neurosurgeon in the Midst of COVID-19 Pandemic Storm: The Italian Experience From the Frontline |pdf=|usr=}}
| |
| − | {{tp|p=32358606|t=ä. Letter: Considerations for Performing Emergent Neurointerventional Procedures in a COVID-19 Environment |pdf=|usr=}}
| |
| − | {{tp|p=32336528|t=ä. La gesti�n de la asistencia neurol�gica en tiempos de la pandemia de COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364119|t=ä. Influencia de la infecci�n SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiqui�tricas: �una pandemia demorada?|pdf=|usr=}}
| |
| − | {{tp|p=32364117|t=ä. Un Servicio de Neurolog�a de un hospital terciario en la pandemia COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355985|t=ä. Letter: Safety Instructions for Neurosurgeons During COVID-19 Pandemic Based on Recent Knowledge and Experience |pdf=|usr=}}
| |
| − | {{tp|p=32355982|t=ä. Letter: Back Pain and Accesses to Emergency Departments During COVID-19 Lockdown in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32355962|t=ä. Letter: The Use of Absorbable Sutures in Neurosurgical Procedures in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355961|t=ä. Letter: COVID-19 Impact on the Medical Student Path to Neurosurgery |pdf=|usr=}}
| |
| − | {{tp|p=32355949|t=ä. Letter: Neurosurgical Patients? Management During the COVID-19 Pandemic?An Institutional Report From an African Neurosurgical Center |pdf=|usr=}}
| |
| − | {{tp|p=32242901|t=ä. Letter: The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm |pdf=|usr=}}
| |
| − | {{tp|p=32347942|t=ä. Letter: Surgical Management of Brain Tumor Patients in the COVID-19 Era |pdf=|usr=}}
| |
| − | {{tp|p=32343340|t=ä. Letter: Neurosurgical Management of Spinal Pathology Via Telemedicine During the COVID-19 Pandemic: Early Experience and Unique Challenges |pdf=|usr=}}
| |
| − | {{tp|p=32335684|t=ä. Letter: The Risk of COVID-19 Infection During Neurosurgical Procedures: A Review of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2) Modes of Transmission and Proposed Neurosurgery-Specific Measures for Mitigation |pdf=|usr=}}
| |
| − | {{tp|p=32335681|t=ä. Letter: Maintaining Neurosurgical Resident Education and Safety During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32335668|t=ä. Letter: COVID-19 Pandemic: Safety Precautions for Stereotactic Radiosurgery |pdf=|usr=}}
| |
| − | {{tp|p=32323725|t=ä. In Reply: Precautions for Endoscopic Transnasal Skull Base Surgery During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32310292|t=ä. Letter: Collateral Pandemic in Face of the Present COVID-19 Pandemic: A Neurosurgical Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32304213|t=ä. Letter: COVID-19 Infection Affects Surgical Outcome of Chronic Subdural Hematoma |pdf=|usr=}}
| |
| − | {{tp|p=32304212|t=ä. Letter: Transmission of COVID-19 During Neurosurgical Procedures?Some Thoughts From the United Kingdom |pdf=|usr=}}
| |
| − | {{tp|p=32302399|t=ä. A COVID-19 Patient Who Underwent Endonasal Endoscopic Pituitary Adenoma Resection: A Case Report |pdf=|usr=}}
| |
| − | {{tp|p=32302398|t=ä. In Reply: Precautions for Endoscopic Transnasal Skull Base Surgery During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302387|t=ä. Letter: Adaptation Under Fire: Two Harvard Neurosurgical Services During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302385|t=ä. Letter: Rongeurs, Neurosurgeons, and COVID-19: How Do We Protect Health Care Personnel During Neurosurgical Operations in the Midst of Aerosol-Generation From High-Speed Drills?|pdf=|usr=}}
| |
| − | {{tp|p=32293678|t=ä. Letter: Precautions for Endoscopic Transnasal Skull Base Surgery During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32293677|t=ä. Letter: Neurosurgery and Coronavirus (COVID-19) Epidemic: Doing our Part |pdf=|usr=}}
| |
| − | {{tp|p=32277754|t=ä. Letter: Academic Neurosurgery Department Response to COVID-19 Pandemic: The University of Miami/Jackson Memorial Hospital Model |pdf=|usr=}}
| |
| − | {{tp|p=32277757|t=ä. Letter: Strategies for Prevention and Control of 2019 Novel Coronavirus Infection Among Medical Staff |pdf=|usr=}}
| |
| − |
| |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32035030|t=2020. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32085839|t=2020. Mental health care for medical staff in China during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32291383|t=2020. Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 2020 During the Outbreak of Coronavirus Disease 2019 (COVID-19) in Hubei, China |pdf=|usr=}}
| |
| − | {{tp|p=32221635|t=ä. Umgang mit psychischer Belastung bei Gesundheitsfachkräften im Rahmen der Covid-19-Pandemie |pdf=|usr=}}
| |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32294078|t=2020. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| Zeile 298: |
Zeile 152: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32236594|t=2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy |pdf=|usr=}}
| |
| − | {{tp|p=31996413|t=2020. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing |pdf=|usr=}}
| |
| − | {{tp|p=32051570|t=2020. Novel coronavirus takes flight from bats?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32376697|t=2020. An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes |pdf=|usr=}}
| |
| − | {{tp|p=32284615|t=ä. The proximal origin of SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32282789|t=2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland |pdf=|usr=}}
| |
| − | {{tp|p=32244041|t=2020. Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids |pdf=|usr=}}
| |
| − | {{tp|p=32088333|t=2020. Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases |pdf=|usr=}}
| |
| − | {{tp|p=32087334|t=2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |pdf=|usr=}}
| |
| − | {{tp|p=32278074|t=ä. Emergency response to the outbreak of COVID-19: the Korean case |pdf=|usr=}}
| |
| − | {{tp|p=32379733|t=2020. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24-April 21, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32379731|t=2020. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32352957|t=2020. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U S Cities, March 27-April 15, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32134909|t=2020. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32324720|t=2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32298247|t=2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32265315|t=2020. 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission |pdf=|usr=}}
| |
| − | {{tp|p=32003551|t=2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany |pdf=|usr=}}
| |
| − | {{tp|p=31995857|t=2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus?Infected Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32329972|t=ä. Asymptomatic Transmission, the Achilles? Heel of Current Strategies to Control Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32182409|t=ä. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 |pdf=|usr=}}
| |
| − | {{tp|p=32289214|t=ä. Spread of SARS-CoV-2 in the Icelandic Population |pdf=|usr=}}
| |
| − | *[https://www.thegatewaypundit.com/2020/05/key-stat-43-u-s-covid-19-deaths-come-0-6-population/ 130fold relativ risk in part of us population]
| |
| − | {{tp|p=32273611|t=ä. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys |pdf=|usr=}}
| |
| − | {{tp|p=31988464|t=2020. China s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response |pdf=|usr=}}
| |
| − | {{tp|p=32284619|t=ä. On the responsible use of digital data to tackle the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32284618|t=ä. Digital technology and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32322102|t=ä. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32257511|t=2020. COVID-19 Pandemic: Public Health Implications in Nepal |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | | | |
| Zeile 339: |
Zeile 161: |
| | {{tp|p=32221514|t=ä. How behavioural science data helps mitigate the COVID-19 crisis |pdf=|usr=}} | | {{tp|p=32221514|t=ä. How behavioural science data helps mitigate the COVID-19 crisis |pdf=|usr=}} |
| | ---- | | ---- |
| − | | + | *'''[[Failure of politics and public health guidance]]''' |
| | + | {{tp|p=32272085|t=2020. Economic sanctions and Iran s capacity to respond to COVID-19 |pdf=|usr=}} |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
